1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BNIT
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Algeta; Bayer; Janssen; Medivation
Honoraria - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Research Funding - Algeta; Bayer
David Bottomley
Honoraria - Bayer
Robert E. Coleman
Honoraria - Bayer; Celgene
Expert Testimony - Novartis
Irene Skjorestad
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Mona Wahba
Employment or Leadership Position - Bayer
Sten Nilsson
Consultant or Advisory Role - Algeta
Other Remuneration - Bayer